Fig. 1 · Structure

Documents & Downloads

TRAM-34

Cat. No. A12783 CAS 289905-88-0

Potassium Channel Blocker

TRAM-34 is a highly selective blocker of intermediate conductance Ca2+-activated K+ channels (KCa3.1) (Kd = 20 nM). Exhibits 200-1500-fold selectivity over KV, BKCa, KCa2, Na+, CRAC and Cl- channels. Suppresses the reactivation of lymphocytes by mitogenic stimuli.

In Stock

Publications for TRAM-34

2 publications citing this product

  1. Samuel Drinkall, .et al. , Glia, 2022, Jul;70(7):1301-1316 PMID: 35353387
  2. Cheong Hoon Seo, .et al. , Transl Res, 2021, Apr 24 PMID: 33905948

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

TRAM-34 inhibits the intermediate-conductance Ca2+-activated potassium channel IKCa1 (KCa3.1). Whole-cell recordings gave a reported Kd of 20 ± 3 nM for cloned human channels and 25 ± 5 nM for native lymphocyte currents. These are functional channel-block values. [1]

Selectivity depends on concentration and assay. Recombinant-enzyme studies found micromolar inhibition of several rat and human CYP isoforms, including substrate-dependent inhibition or stimulation of CYP3A4. TRAM-34 should not be described as universally free of CYP effects. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
IKCa1 (KCa3.1) Kd 20 nM

Cellular Effect

Cell Line Activity Value Description Reference
COS-7 IC50 0.02 μM Inhibition of human cloned IK1 expressed in african green monkey COS7 cells by whole cell patch clamp assay [PMID: 19282171]
HaCaT EC50 40 μM Inhibition of human HaCaT cell proliferation after 48 hrs [PMID: 19282171]
PBMC EC50 0.025 μM Immunosuppressant activity in human effector memory T cells of PBMC assessed as inhibition of anti-CD3 antibody-induced cell proliferation by ELISA in presence of 5 uM Kv1.3-blocker PAP1 [PMID: 19282171]

TRAM-34 Research Summary

This section summarizes 5 in vitro studies and 1 in vivo study of TRAM-34 from 4 published references. In vitro models include COS-7 cells expressing human IKCa1 and activated human T lymphocytes; recombinant human CYP3A4 assayed with DBF, BFC or lovastatin.

TRAM-34 In Vitro Studies

In human PBMC assays, TRAM-34 inhibited thymidine incorporation more potently after lymphocyte preactivation than in resting cells, with substantial donor and stimulus dependence. Inhibition of resting-cell activation required 5–10 µM, which the authors considered potentially nonspecific. [1]

Activity is model-dependent: TRAM-34 at 10 µM did not reduce ATP- or silica-induced IL-1β release from primed primary mouse macrophages in a potassium-channel inhibitor screen. [3]

Functional inhibition of cloned and native IKCa1 currents

Cell-based study · COS-7 cells expressing human IKCa1 and activated human T lymphocytes [1]

Whole-cell recordings established nanomolar functional channel block. The tested channel panel supports relative ion-channel selectivity, not absence of other molecular targets.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cloned human IKCa1 current inhibitionKd 20 ± 3 nM[1]
Native IKCa current inhibition in activated human T lymphocytesKd 25 ± 5 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response; Figure 3A illustrates 25 and 50 nM
Exposure duration
Block reached equilibrium in 3–6 min (triarylmethanes)
Method
External application during whole-cell patch clamp
Reported limits
Vehicle and meaning of the reported Kd ± terms are not specified for this endpoint in the retrieved main text.
Methods and source locations

Compound reported in the paper: TRAM-34; Compound label in the paper: 6b

Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.

Figure 3A-D; Table 1; Electrophysiology; Results: TRAM-34 Is a Highly Selective Inhibitor

Cloned human IKCa1 current inhibition: Hill fit to slope-conductance reduction at −80 mV; 1 µM pipette free Ca2+; Hill coefficient 1.2; 15 cells — Figure 3A-B and caption; Results channel-block paragraph

Native IKCa current inhibition in activated human T lymphocytes: Whole-cell patch clamp; residual Kv1.3 current blocked by ShK-Dap22 — Table 1, lymphocyte IK row; Figure 3D; Electrophysiology

Activation-state dependence of lymphocyte mitogenesis inhibition

Cell-based study · Human peripheral blood mononuclear cells from different donors; resting versus 48-h preactivated cells [1]

TRAM-34 suppressed mitogen-restimulated thymidine incorporation more potently in preactivated cells than in resting cells. Responses varied by donor and stimulus.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of thymidine incorporation after anti-CD3 restimulation of preactivated cellsEC50 Sensitive donors: 295 (±130) nM; less sensitive donors: 910 (±70) nM[1]
Inhibition after PMA plus ionomycin restimulation of preactivated cellsEC50 Sensitive donors: 85 (±30) nM; less sensitive donors: 830 (±300) nM[1]
Activation of resting human lymphocytesConcentration associated with inhibition 5–10 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response, not a fixed treatment dose
Exposure duration
60-min drug preincubation; 48-h mitogen stimulation/restimulation; thymidine during final 6 h
Method
Anti-CD3 antibody (5 ng/mL) or PMA (10 nM) plus ionomycin (175 nM) stimulation; corresponding preactivation for 48 h
Co-treatment
Mitogens are assay stimuli; cyclosporin A combination in Figure 4C is not adopted.
Reported limits
Drug vehicle and statistical meaning of EC50 ± terms not specified in retrieved assay text; donor subgroup sizes for fitted EC50 means are not given.
Methods and source locations

Compound reported in the paper: TRAM-34; Compound label in the paper: 6b

Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.

Figure 4A-B and caption; [3H]Thymidine Incorporation Assay; Results: TRAM-34 Suppresses Human T Lymphocyte Activation

Inhibition of thymidine incorporation after anti-CD3 restimulation of preactivated cells: [3H]Thymidine incorporation; Figure 4 includes preactivated cells from six donors and resting cells from three donors — Results lymphocyte activation paragraph; Figure 4A and caption

Inhibition after PMA plus ionomycin restimulation of preactivated cells: [3H]Thymidine incorporation in mixed T/B lymphocyte-containing PBMC population — Results lymphocyte activation paragraph; Figure 4B and caption

Activation of resting human lymphocytes: Little effect at nanomolar concentrations; authors suggest inhibition at higher concentrations may be nonspecific — Results lymphocyte activation paragraph; Figure 4A-B, open symbols

Rat and human CYP isoform inhibition panel

Biochemical assay · Recombinant rat CYP2C6, CYP2C11, CYP1A2 and CYP2B1; human CYP2C19, CYP19A1, CYP1A2 and CYP2B6 [2]

TRAM-34 inhibited several CYP isoforms at micromolar concentrations, while rat/human CYP1A2 and human CYP19A1 showed little or no inhibition up to 80 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Rat CYP isoform inhibitionIC50 CYP2C6: 2.9 µM; CYP2C11: 12.6 µM; CYP2B1: 3.0 µM[2]
Human CYP isoform inhibitionIC50 CYP2C19: 1.8 µM; CYP2B6: 0.9 µM[2]
Rat/human CYP1A2 and human CYP19A1 activityLimiting result Little or no inhibition up to 80 µM TRAM-34[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response up to 80 µM
Exposure duration
Table 1: preincubation 10 or 15 min; reaction 17 or 30 min, depending on isoform
Method
Fluorescent product assays at 37°C; substrate concentrations near known Km; no-inhibitor control
Vehicle
1% acetonitrile in fluorescence assays
Reported limits
No in vivo drug-interaction magnitude follows from this recombinant-enzyme panel.
Methods and source locations

Compound reported in the paper: TRAM-34; Compound label in the paper: TRAM-34

Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.

Materials and Methods; Table 1; Results and Figures 1-2 with captions

Rat CYP isoform inhibition: EFC for CYP2C6/2B1; DBF for CYP2C11. TRAM-34 points: mean ± SEM of 3 experiments in triplicate; clotrimazole comparator — Table 1; Figure 1A,B,D and caption; Results rat CYP activity

Human CYP isoform inhibition: DBF for CYP2C19; EFC for CYP2B6. TRAM-34 points: mean ± SEM of 3 experiments in triplicate; clotrimazole positive control — Table 1; Figure 2A,D and caption; Results human CYP activity

Rat/human CYP1A2 and human CYP19A1 activity: Positive comparator inhibition demonstrated for human CYP1A2 (fluvoxamine) and CYP19A1 (ketoconazole); rat CYP1A2 clotrimazole response was partial; TRAM-34 did not significantly alter product fluorescence at 30 or 100 µM — Figures 1C and 2B-C; Methods fluorescence interference check

Substrate-dependent modulation of human CYP3A4

Biochemical assay · Recombinant human CYP3A4 assayed with DBF, BFC or lovastatin [2]

TRAM-34 inhibited CYP3A4 with DBF and lovastatin but stimulated BFC turnover. A blanket claim that TRAM-34 lacks CYP activity is therefore unsupported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CYP3A4-mediated DBF turnoverIC50 3.6 µM[2]
CYP3A4-mediated BFC turnoverDirection Concentration-dependent stimulation[2]
Formation of two lovastatin metabolites by CYP3A4IC50 6′β-hydroxy lovastatin: 0.92 µM; 6′-exomethylene lovastatin: 0.64 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response
Exposure duration
DBF: 10-min preincubation, 20-min reaction; BFC: 15-min preincubation, 5-min reaction; lovastatin: 20-min reaction
Method
Fluorescent DBF/BFC turnover or LC-MS/MS quantification of lovastatin metabolites
Vehicle
Fluorescence assays contained 1% acetonitrile
Reported limits
Do not transfer fluorescence-assay solvent conditions to the separate LC-MS/MS assay.
Methods and source locations

Compound reported in the paper: TRAM-34; Compound label in the paper: TRAM-34

Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.

Table 1; Figures 3-4 and captions; CYP3A4 Assay with LVS as Substrate; Results CYP3A4 activity

CYP3A4-mediated DBF turnover: DBF 1 µM; mean ± SEM of 3 experiments in triplicate; ketoconazole positive control — Table 1; Figure 3A and caption

CYP3A4-mediated BFC turnover: BFC 50 µM; mean ± SEM of 3 experiments in triplicate; ketoconazole inhibited turnover — Table 1; Figure 3B and caption; Results CYP3A4 activity

Formation of two lovastatin metabolites by CYP3A4: Lovastatin 10 µM; LC-MS/MS; mean ± SEM of 3 experiments in duplicate; ketoconazole 10 µM inhibited both by >85% — Figure 4 printed curve labels and caption; Table 1; CYP3A4 assay methods

TRAM-34 negative comparator in macrophage IL-1β release

Cell-based study · Primary mouse bone marrow-derived macrophages, LPS-primed and challenged with ATP or silica [3]

TRAM-34 did not reduce IL-1β release in this comparator screen, whereas MCC950 and several broader potassium-channel inhibitors reduced release.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-1β release after ATP or silica challengeNegative result No impact reported for TRAM-34 10 µM under these conditions[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM TRAM-34
Exposure duration
15-min pretreatment; ATP challenge 1 h or silica challenge 4 h
Method
IL-1β ELISA of supernatants after ATP (5 mM) or silica (300 µg/mL) challenge
Vehicle
1% (vol/vol) DMSO
Reported limits
No direct KCa3.1 target-engagement measurement accompanies the negative TRAM-34 comparator; no universal absence of activity is inferred.
Methods and source locations

Compound reported in the paper: TRAM-34; Compound label in the paper: TRAM-34

Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.

Methods 2.1, 2.3, 2.12; Results 3.2; Figure 1ai-ii and caption

IL-1β release after ATP or silica challenge: ATP n=4; silica n=5; mean ± SEM; one-way ANOVA with Dunnett post hoc analysis. Vehicle and MCC950 comparator groups in Figure 1ai-ii — Figure 1ai-ii and caption; Results 3.2

TRAM-34 In Vivo Studies

In male Wistar rats subjected to transient cerebral ischemia, TRAM-34 at 10 or 40 mg/kg intraperitoneally twice daily, starting 12 h after reperfusion for a reported 7-day course, reduced H&E-defined infarct area versus vehicle. Reduced hemisphere shrinkage was significant only at 40 mg/kg. These findings are specific to this preclinical model. [4]

Delayed TRAM-34 treatment in a rat ischemia/reperfusion model

Animal study · Adult male Wistar rats; 90-min middle cerebral artery occlusion followed by reperfusion [4]

Both TRAM-34 dose groups had smaller H&E-defined infarct areas than vehicle under the reported delayed-treatment schedule. Brain-shrinkage reduction reached significance only at 40 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total hemisphere infarct area by H&EMean ± SEM Vehicle: 22.6 ± 3.6% (n=8); 10 mg/kg: 11.3 ± 2.8% (n=6), P=0.039; 40 mg/kg: 8.1 ± 1.9% (n=8), P=0.004[4]
Hemisphere shrinkage reduction versus vehicleSignificance 10 mg/kg: P=0.11; 40 mg/kg: P=0.013[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Twice daily
Treatment course
7 days, starting 12 h after reperfusion (nominal schedule reported)
Vehicle
Miglyol 812 neutral oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
TRAM-34 10 mg/kgVehicle, Miglyol 812 at 1 µL/g; n=8Total hemisphere infarct area 11.3 ± 2.8% (n=6) versus vehicle 22.6 ± 3.6% (n=8); mean ± SEM, P=0.039. Shrinkage reduction not significant (P=0.11).[4]
TRAM-34 40 mg/kgVehicle, Miglyol 812 at 1 µL/g; n=8Total hemisphere infarct area 8.1 ± 1.9% (n=8) versus vehicle 22.6 ± 3.6% (n=8); mean ± SEM, P=0.004. Shrinkage reduction significant (P=0.013).[4]
TRAM-34 10 mg/kg
Model: Adult male Wistar rats; 90-min MCAO with reperfusion
Reported limits: No clinical efficacy inference; randomized allocation/blinded infarct assessment not described in the retrieved main methods.
TRAM-34 40 mg/kg
Model: Adult male Wistar rats; 90-min MCAO with reperfusion
Reported limits: No clinical efficacy inference; randomized allocation/blinded infarct assessment not described in the retrieved main methods.
Methods and source locations

Compound reported in the paper: TRAM-34; Compound label in the paper: TRAM-34

Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.

MCAO methods; Assessment of Infarct Area; Statistical Analysis; Figure 3 and caption; Results delayed-treatment cohort

Total hemisphere infarct area by H&E: Summed infarct pixels across eight coronal levels relative to control hemisphere pixels; one-way ANOVA and Tukey pairwise comparisons — Results delayed 12-hour treatment cohort; Figure 3A-B and caption

Hemisphere shrinkage reduction versus vehicle: Same histological cohort; no exact percent shrinkage estimated from bars — Results delayed-treatment cohort; Figure 3C

TRAM-34 10 mg/kg · MCAO methods; Figure 3A-C and caption; Results delayed 12-hour treatment cohort

TRAM-34 40 mg/kg · MCAO methods; Figure 3A-C and caption; Results delayed 12-hour treatment cohort

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 289905-88-0
Applications Potassium Channel Blocker
Formula C22H17ClN2
Molecular Weight 344.84
SMILES
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 0.36 mg/mL (1.04 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
2% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

TRAM-34 Research References

  1. [1] Wulff H, Miller MJ, Hansel W, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A (2000). PMID: 10884437 DOI: 10.1073/pnas.97.14.8151 Source material
  2. [2] Agarwal JJ, Zhu Y, Zhang QY, et al. TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One (2013). PMID: 23667566 DOI: 10.1371/journal.pone.0063028 Source material
  3. [3] Drinkall S, Lawrence CB, Ossola B, et al. The two pore potassium channel THIK-1 regulates NLRP3 inflammasome activation. Glia (2022). PMID: 35353387 DOI: 10.1002/glia.24174 Source material
  4. [4] Chen YJ, Raman G, Bodendiek S, et al. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab (2011). PMID: 21750563 DOI: 10.1038/jcbfm.2011.101 Source material

Publications

2 publications citing this product

  1. Samuel Drinkall, .et al. , Glia, 2022, Jul;70(7):1301-1316 PMID: 35353387
  2. Cheong Hoon Seo, .et al. , Transl Res, 2021, Apr 24 PMID: 33905948

Added to your cart

View Cart Checkout
Loading...